Table 2

Associations between baseline plasma AGEs and incident primary and secondary end points (n = 339)

ModelPrimary end point (85 events)Secondary end point (82 events)
HR95% CIP valueHR95% CIP value
11.331.05–1.690.0181.341.06–1.690.013
21.361.08–1.730.0111.341.06–1.690.013
3a1.351.07–1.710.0131.361.07–1.720.011
3b1.311.03–1.660.0261.250.99–1.590.060
31.301.03–1.660.0291.271.00–1.620.047
4a1.310.99–1.730.0571.270.95–1.680.103
4b1.261.00–1.610.0551.240.98–1.580.076
4c1.311.00–1.620.0281.261.00–1.590.051
4d1.301.02–1.660.0361.281.01–1.640.046
  • Primary end point was a combined end point of fatal and nonfatal CVD, and the secondary end point was all-cause mortality. During the course of follow-up, 82 individuals died; 85 suffered a fatal (n = 48) and/or nonfatal (n = 53) CVD event. Model 1 is adjusted for age, sex, A1C, case-control status, and duration of diabetes; model 2: model 1 + BMI, MAP, smoking status, and total cholesterol; model 3a: model 2 + RAAS inhibitors; model 3b: model 2 + other antihypertensive agents; model 3: model 2 + RAAS inhibitors and other antihypertensive agents; model 4a: model 3 + eGFR by abbreviated modification of diet in renal disease equation and Ln-UAE rate; model 4b: model 3 + low-grade inflammation score; model 4c: model 3 + endothelial dysfunction score; model 4d: model 3 + pulse pressure.